MDMerete Dam

Merete Dam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Merete Dam has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Early prediction of subsequent peg‐asparaginase inactivation in acute lymphoblastic leukaemia patients—A NOPHO ALL2008 study

    by Merete Dam, Maddalena Centanni, Daniel Centanni, Lena E. Friberg, Mats O. Karlsson, Line S. Lynggaard, Inga M. Johannsdottir, Kristi Lepik, Goda E. Vaitkeviciene, Laimonas Griskevicius, et al.

    Summary: Polyethylene glycol (peg)‐asparaginase plays a crucial role in acute lymphoblastic leukaemia (ALL) treatment, yet its associated toxicity often leads to treatment discontinuation, elevating relapse risk. Hypersensitivity with inactivation of asparaginase is common and often associated with severe allergic reactions. This study aims to comprehensively analyse asparaginase enzyme activity (AEA) pharmacokinetics, validate a previously developed pharmacokinetic model based on intravenous administration and evaluate its capability to detect changes in clearance before inactivation in patients treated with intramuscular peg‐asparaginase. The study, covering 644 patients aged 1–45 with ALL under the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL2008 Protocol (February 2017–December 2022, in Nordic and Baltic countries), included 3003 AEA samples. Sampling occurred 14 days post peg‐asparaginase doses, with additional sampling between doses. The incidence of inactivation was 15.2%. Utilizing the pharmacokinetic model, estimates revealed an 87.8% sensitivity and 65.5% specificity for detecting increased peg‐asparaginase clearance over time in patients experiencing inactivation. Identification of increased clearance preceding inactivation in the NOPHO ALL2008 dataset highlights the potential of pharmacokinetic sampling to predict inactivation and enable timely intervention before clinical manifestation, with further refinement and inclusion of additional protocols into a unified model offering the promise of improving clinicians' ability to assess individual patient risk.

  • Open Access

    Sequelae and post‐thrombotic syndrome after venous thromboembolism in acute lymphoblastic leukemia survivors treated on the NOPHO ALL2008 protocol

    by Merete Dam, Line Stensig Lynggaard, Ólafur G. Jónsson, Sonata Saulyte Trakymiene, Katrin Palk, Kirsten Jarvis, Liv Andrés‐Jensen, Ruta Tuckuviene, Birgitte Klug Albertsen

    The treatment of acute lymphoblastic leukemia (ALL) is frequently complicated by toxicity, including venous thromboembolism (VTE) affecting roughly 8% of patients. VTE can lead to post‐thrombotic syndrome (PTS), a group of signs and symptoms developed as a complication to deep venous thrombosis (DVT), imposing risk of permanent disability and reduced quality of life (QoL). PTS prevalence ranges from 0% to 70%, reflecting very heterogenous cohorts and assessment tools. We aimed to estimate sequelae, including PTS and QoL in children and adults (p = .9). This study underscores the need for comprehensive population‐based investigations with validation of PTS instruments in ALL survivors.


  • Open Access

    Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia

    by Merete Dam, Maddalena Centanni, Lena E. Friberg, Daniel Centanni, Mats O. Karlsson, Line Stensig Lynggaard, Inga Maria Johannsdottir, Hilde Skuterud Wik, Johan Malmros, Goda Elizabeta Vaitkeviciene, et al.

    Asparaginase is an essential component of acute lymphoblastic leukemia (ALL) therapy, yet its associated toxicities often lead to treatment discontinuation, increasing the risk of relapse. Hypersensitivity reactions include clinical allergies, silent inactivation, or allergy-like responses. We hypothesized that even moderate increases in asparaginase clearance are related to later inactivation. We therefore explored mandatory monitoring of asparaginase enzyme activity (AEA) in patients with ALL aged 1–45 years treated according to the ALLTogether pilot protocol in the Nordic and Baltic countries to relate mean AEA to inactivation, to build a pharmacokinetic model to better characterize the pharmacokinetics of peg-asparaginase and assess whether an increased clearance relates to subsequent inactivation. The study analyzed 1631 real-time AEA samples from 253 patients, identifying inactivation in 18.2% of the patients. This inactivation presented as mild allergy (28.3%), severe allergy (50.0%), or silent inactivation (21.7%). A pharmacokinetic transit compartment model was used to describe AEA-time profiles, revealing that 93% of patients with inactivation exhibited prior increased clearance, whereas 86% of patients without hypersensitivity maintained stable clearance throughout asparaginase treatment. These findings enable prediction of inactivation and options for either dose increments or a shift to alternative asparaginase formulations to optimize ALL treatment strategies.


  • Open Access

    Increase in PEG-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia

    by Birgitte Albertsen, Merete Dam, Maddalena Centanni, Lena Friberg, Daniel Centanni, Mats Karlsson, Line Stensig Lynggaard, Inga Maria Johannsdottir, Hilde Wik, Johan Malmros, et al.

    Asparaginase is an essential component of acute lymphoblastic leukemia (ALL) therapy, yet its associated toxicities often lead to treatment discontinuation, increasing the risk of relapse. Hypersensitivity reactions include clinical allergies, silent inactivation, or allergy-like responses. We hypothesized that even moderate increases in asparaginase clearance are related to later inactivation. We therefore explored mandatory monitoring of asparaginase enzyme activity (AEA) in patients with ALL aged 1–45 years treated according to the ALLTogether pilot protocol in the Nordic and Baltic countries to relate mean AEA to inactivation, to build a pharmacokinetic model to better characterize the pharmacokinetics of PEG-asparaginase and assess whether an increased clearance relates to subsequent inactivation. The study analysed 1 631 real-time AEA samples from 253 patients, identifying inactivation in 18.2% of the patients. This inactivation presented as mild allergy (28.3%), severe allergy (50.0%), or silent inactivation (21.7%). A pharmacokinetic transit compartment model was used to describe AEA-time profiles, revealing that 93% of patients with inactivation exhibited prior increased clearance, whereas 86% of patients without hypersensitivity maintained stable clearance throughout asparaginase treatment. These findings enable prediction of inactivation and options for either dose increments or a shift to alternative asparaginase formulations to optimize ALL treatment strategies.